Targeted Therapy Paradigm Grows in NSCLC, While Overcoming Resistance Represents Next HurdleJune 29th 2021
The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.
Using NGS to Inform More Than Diagnosis in Myeloid MalignanciesJune 29th 2021
Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.
New Diagnostic Algorithms Have Prognostic Implications in Endometrial CancerJune 25th 2020
Endometrial cancer tumor types are traditionally categorized through a combination of histologic molecular subtyping and clinical staging; however, the incorporation of new diagnostic algorithms may have clinical implications for treatment.
Assessing the Actionability of KRAS Mutations in NSCLCJune 23rd 2020
KRAS mutations are found in approximately in 25% of all NSCLC, and it was not until recently that the previously coined “undruggable target” showed signals of actionability with KRAS mutation–specific therapy, tumor-suppressor–specific therapy, and anti-inflammatory therapy.